Quintana Daniel S, Dieset Ingrid, Elvsåshagen Torbjørn, Westlye Lars T, Andreassen Ole A
NORMENT, KG Jebsen Centre for Psychosis Research, Division of Mental Health and Addiction, University of Oslo, and Oslo University Hospital, Oslo, Norway.
NORMENT, KG Jebsen Centre for Psychosis Research, Division of Mental Health and Addiction, University of Oslo, and Oslo University Hospital, Oslo, Norway.
Front Neuroendocrinol. 2017 Apr;45:1-10. doi: 10.1016/j.yfrne.2016.12.004. Epub 2017 Jan 1.
There is growing interest in using intranasal oxytocin (OT) to treat social dysfunction in schizophrenia and bipolar disorders (i.e., psychotic disorders). While OT treatment results have been mixed, emerging evidence suggests that OT system dysfunction may also play a role in the etiology of metabolic syndrome (MetS), which appears in one-third of individuals with psychotic disorders and associated with increased mortality. Here we examine the evidence for a potential role of the OT system in the shared risk for MetS and psychotic disorders, and its prospects for ameliorating MetS. Using several studies to demonstrate the overlapping neurobiological profiles of metabolic risk factors and psychiatric symptoms, we show that OT system dysfunction may be one common mechanism underlying MetS and psychotic disorders. Given the critical need to better understand metabolic dysregulation in these disorders, future OT trials assessing behavioural and cognitive outcomes should additionally include metabolic risk factor parameters.
使用鼻内催产素（OT）治疗精神分裂症和双相情感障碍（即精神障碍）中的社会功能障碍正受到越来越多的关注。虽然OT治疗的结果好坏参半，但新出现的证据表明，OT系统功能障碍也可能在代谢综合征（MetS）的病因中起作用，MetS出现在三分之一的精神障碍患者中，并与死亡率增加相关。在这里，我们研究了OT系统在MetS和精神障碍共同风险中的潜在作用的证据，以及其改善MetS的前景。通过多项研究来证明代谢风险因素和精神症状的重叠神经生物学特征，我们表明OT系统功能障碍可能是MetS和精神障碍的一个共同潜在机制。鉴于迫切需要更好地理解这些疾病中的代谢失调，未来评估行为和认知结果的OT试验应额外纳入代谢风险因素参数。
